OTHER
placebo
placebo administered subcutaneously (SC) once a week.
Status
Completed
Phase
Phase 3
Enrollment
319
Locations
1
Results
Not posted
Publications
0
Study summary
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the effectiveness and safety of IBI362 in patients with type 2 diabetes (T2D) with poor glycemia control only through diet and exercise. This study plans to enroll about 300 T2D subjects who still fail to meet the HbA1c standard after at least 2 months of simple diet and exercise control. During the whole study, subjects will be required to maintain diet and exercise control. The whole trial period includes a 2-week screening period, a 6-week introduction period, a 24 week double-blind treatment period, a 24 week study extension period and a 4-week safety follow-up period. Subjects who met the randomization criteria will be randomly assigned to the IBI362 4.0 mg group, the IBI362 6.0 mg group and the placebo group at 1:1:1. The randomization stratification factors were (V3) HbA1c\<8.5% or HbA1c ≥ 8.5% before randomization.
Interventions
OTHER
placebo administered subcutaneously (SC) once a week.
DRUG
IBI362 administered subcutaneously (SC) once a week.
Timeline
First posted
Nov 28, 2022
Study start
Jan 6, 2023
Primary completion
Oct 25, 2023
Study completion
May 9, 2024
Results posted
Not reported
Registry updated
Aug 20, 2024
Outcomes
HbA1c change from baseline at week 24
Time frame · Baseline, 24 weeks
Proportion of subjects with HbA1c<7.0% at week 24
Time frame · Baseline, 24 weeks
Safety, Incidence and severity of adverse events and correlation with study drug;
Time frame · Baseline to 52 weeks
Time to peak plasma concentration (Tmax)
Time frame · Baseline to 52 weeks
Time to peak plasma concentration (Cmax)
Time frame · Baseline to 52 weeks
area under curve (AUC)
Time frame · Baseline to 52 weeks
volume distribution (V)
Time frame · Baseline to 52 weeks
half-life (half-life, T1/2)
Time frame · Baseline to 52 weeks
clearance rate (clearance, CL)
Time frame · Baseline to 52 weeks
To assess changes in PD parameters fasting insulin at different time points before and after administration.
Time frame · Baseline to 52 weeks
To assess changes in PD parameters fasting C-peptide at different time points before and after administration.
Time frame · Baseline to 52 weeks
Eligibility
Inclusion Criteria: 1. T2D was diagnosed according to WHO standards in 1999 for at least 2 months 2. Age ≥ 18 when signing the informed consent form 3. The blood glucose was not well controlled after simple diet and exercise within 2 months before screening, and the local laboratory tested 7.5% ≤ HbA1c ≤ 10.5% during screening 4. Maintain a stable diet and exercise lifestyle during the study 5. Subjects voluntarily signed the informed consent form and agreed to strictly follow the requirements of this protocol Exclusion Criteria: 1. Subjects who the investigator thinks may be allergic to the components in the study drug or similar drugs 2. Weight change\>5% within 12 weeks before screening (chief complaint) 3. Used any oral hypoglycemic drugs within 2 months before screening; ≥ 3 oral hypoglycemic drugs have been used together more than 2 months before screening 4. Previous diagnosis of type 1 diabetes (including adult latent autoimmune diabetes), special type diabetes or gestational diabetes 5. There are active or untreated malignant tumors within 5 years before screening, or patients are in remission of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery) 6. Mental illness existed in the past or at the time of screening, and the researcher thinks it is not suitable to participate in this study 7. Pregnant or lactating women, or men or women who are fertile and unwilling to use contraception throughout the study period 8. The investigator believes that the subject has any other factors that may affect the efficacy or safety evaluation of this study and is not suitable to participate in this study
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
West China Hospital · Metabolic Dysfunction-Associated Steatohepatitis · Hepatic Steatosis
Phase 2 / Phase 3
Not yet recruiting
60
2026-07
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
Tianjin Medical University · Type 2 Diabetes Mellitus (T2DM) · Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
Not applicable
Not yet recruiting
72
2026-07
Eli Lilly · Alcohol Use Disorder
Phase 2
Completed
308
2026-07
China National Center for Cardiovascular Diseases · Obesity & Overweight · Coronary Heart Disease
Phase 4
Not yet recruiting
116
2026-06
Shandong Provincial Hospital · Prediabetes · Impaired Fasting Glucose
Phase 4
Not yet recruiting
150
2026-06
Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes · Obesity
Phase 3
Completed
349
2026-06
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
200
2026-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.